1
|
Yatsenko T, Celtik K, Lundon D, Zisman A, Djordjevic M, Purohit R. Associations in prostate size in transgender women on hormone therapy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00876-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Zisman A, Razdan S, Siegal A, Sljivich M, Bieber C, Ho P, Valenzuela R. Midline submuscular penile prosthesis reservoir placement for patients with bilateral inaccessible inguinal rings: Technique and outcomes. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01302-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Katz R, Abu Ahmed M, Safadi A, Roizman S, Zisman A, Kabha M, Dekel Y, Baniel J, Aharoni S. The Butterfly transurethral device for BPH - more than one year experience. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00808-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Verhovsky G, Zisman A, Sabler I. Tubeless ureterorenoscopy. Our experience using 120-W laser and dusting technique. Postoperative pain, complications and readmissions. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01114-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Katz R, Abu Ahmed M, Safadi A, Roizman S, Zisman A, Maharan K, Dekel Y, Baniel J, Aharoni S. The Butterfly: A novel minimally invasive transurethral retraction device for BPH. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00439-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Kord E, Leshno M, Zisman A, Haifler M. The effects of Robotic surgery, Urinary diversion and early recovery protocol on costs of Radical cystectomy – a complete cost effectiveness analysis. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01195-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Siegmund T, Borck A, Zisman A, Kress S. Charakteristika von Patienten mit einem höheren Nüchternblutzucker am Morgen im Vergleich zum abendlichen Vergleichswert (negativer BeAM-Wert) unter einer Basalinsulin-unterstützten oralen Therapie (BOT). DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Kress S, Borck A, Zisman A, Siegmund T. Ein großer Unterschied zwischen den Blutzuckerwerten zur Nacht und am nächsten Morgen (hoher BeAM-Wert) weist auf die Notwendigkeit der Initiierung und Intensivierung einer prandialen Therapie hin. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Bahi R, Pignot G, Hammoudi Y, Bensalah K, Oger E, Laguna P, Barwari K, Bessède T, Rigaud J, Roupret M, Bernhard JC, Long JA, Zisman A, Berger J, Paparel P, Lechevallier E, Bertini R, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez A, Patard JJ. L’ischémie a un impact limité sur la fonction rénale après néphrectomie partielle sur rein unique chez les patients sans insuffisance rénale préopératoire. Prog Urol 2015; 25:27-33. [DOI: 10.1016/j.purol.2014.09.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 09/01/2014] [Accepted: 09/12/2014] [Indexed: 01/20/2023]
|
10
|
Pignot G, Bahi R, Bensalah K, Oger E, Laguna P, Barwari K, Rigaud J, Rouprêt M, Bernhard J, Long J, Zisman A, Berger J, Paparel P, Lechevallier E, Bertini R, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez A, Patard J. [Not Available]. Prog Urol 2014; 24:822. [PMID: 26461614 DOI: 10.1016/j.purol.2014.08.087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- G Pignot
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - R Bahi
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | - P Laguna
- AMC University Hospital, Amsterdam, Pays-Bas
| | - K Barwari
- AMC University Hospital, Amsterdam, Pays-Bas
| | | | | | | | | | - A Zisman
- Tel Aviv University, Tel Aviv, Israël
| | | | | | | | - R Bertini
- Vita-Salute San Raffaele, Milan, Italie
| | | | - A Bex
- AMC University Hospital, Amsterdam, Pays-Bas
| | - R Farfara
- Bnai Zion Medical Center, Haifa, Israël
| | | | - A Rodriguez
- University of South Florida, Tampa, Etats-Unis
| | - J Patard
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
11
|
Woo V, Shaefer C, Brath H, Digenio A, Lin J, Prasanna Kumar K, Zisman A. Lixisenatide Reduces BeAM Value (Difference Between Bedtime (Be) and Next-Day Pre-Breakfast (AM) Glucose): A Clinical Indicator for Initiation of Prandial Therapy. Can J Diabetes 2014. [DOI: 10.1016/j.jcjd.2014.07.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
Verhoest G, Patard J, Oger E, Rioux-Leclercq N, Peyronnet B, Bessède T, Laguna P, Barwari K, Rigaud J, Roupret M, Coffin G, Bernhard J, Long J, Zisman A, Berger J, Paparel P, Maurin C, Lechevallier E, Bertini R, Ouzaid I, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez A, Bensalah K. Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional study. Urol Oncol 2014; 32:28.e21-6. [DOI: 10.1016/j.urolonc.2012.10.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Revised: 10/04/2012] [Accepted: 10/05/2012] [Indexed: 11/27/2022]
|
13
|
Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 2009; 76:442-6. [PMID: 19420966 DOI: 10.1159/000217264] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 09/22/2008] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Management of castration-resistant prostate cancer after docetaxel has become an unmet need for which various agents have been investigated. We report our experience with a paclitaxel-based regimen. METHODS From February 2004 to November 2007, 15 patients (PTS) received paclitaxel 80 mg/m(2) weekly on day 1, carboplatin (AUC = 6) on day 1 every 21 days and estramustine 140 mg on days -1, 0 and 1 every week. RESULTS Patient characteristics are: median age 67 years (range 44-81), median performance status (Eastern Cooperative Oncology Group) 1 (range 0-2) and median prostate-specific antigen 67.5 ng/ml (range 1.5-480). All PTS had soft-tissue and 12 (80%) also had osseous disease. A >50% decrease in prostate-specific antigen levels occurred in 9 PTS (60%, 95% CI 32-84). Responses included a partial response in 6 (40%, 95% CI 16-68) and stable disease in 5 PTS (33%). Median duration of progression-free survival was 4.0 months (range 1.1-13) and median survival was 14.6 months. After a median of 4 cycles (range 1-7), significant toxicity included fatigue grade 3 in 2 PTS (13%), neuropathy grade 2 and grade 4 in 1 patient each, and a single episode of grade 3 edema. Myelosuppression was mild. Two PTS (13%) had urinary tract infection and 1 patient neutropenic fever. One patient died due to brain hemorrhage. CONCLUSIONS Administration of second-line paclitaxel-based chemotherapy after docetaxel therapy is active in PTS with castration-resistant prostate cancer. This regimen is too toxic for palliative therapy. Careful patient selection is needed when this regimen is considered for therapy in these PTS.
Collapse
Affiliation(s)
- A Sella
- Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel.
| | | | | | | |
Collapse
|
14
|
Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou C, Lobel B, Guillé F, Chopin D, Mulders P, Wood C, Swanson D, Figlin R, Belldegrun A, Pantuck A. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. J Urol 2006. [DOI: 10.1016/s0022-5347(05)00434-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- J.-J. Patard
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - E. Leray
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - N. Rioux-Leclercq
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - L. Cindolo
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - V. Ficarra
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - A. Zisman
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - A. De La Taille
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - J. Tostain
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - W. Artibani
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - C.C. Abbou
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - B. Lobel
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - F. Guillé
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - D.K. Chopin
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - P.F.A. Mulders
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - C.G. Wood
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - D.A. Swanson
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - R.A. Figlin
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - A.S. Belldegrun
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - A.J. Pantuck
- Departments of Urology, Public Health and Pathology, Rennes University Hospital, Rennes and Departments of Urology, CHU Honri Mondor, Creteil and North Hospital. CHU Saint-Etienne, Saint-Etienne, France, Departments of Urology and Bostestics. UCLA School of Medicine, Los Angeles, California, and Departments of Urology, Medical School of University Federico II, Naples and University of Verons, Verona, Italy, and University Medical Center Nijmegen, Nijmegen, The Netherlands
| |
Collapse
|
15
|
Pantuck A, Zisman A, Dorey F, Chao D, Han K, Said J, Gitlitz B, Belldegrun A, Figlin R. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Urol Oncol 2004. [DOI: 10.1016/j.urolonc.2003.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Pantuck A, Zisman A, Dorey F, Chao D, Han K, Said J, Gitlitz B, Figlin R, Belldegrun A. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. Urol Oncol 2004. [DOI: 10.1016/j.urolonc.2003.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Affiliation(s)
- D Leibovici
- Department of Urology, Assaf-Harofeh Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Zerifin, 70300, Israel
| | | | | | | |
Collapse
|
18
|
Zisman A. [Laparoscopic radical prostatectomy for prostate cancer--a trend or a surgical anecdote?]. Harefuah 2001; 140:1187-90. [PMID: 11789306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
19
|
Abstract
Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.
Collapse
Affiliation(s)
- M H Bui
- University of California School of Medicine, Department of Urology, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA
| | | | | | | | | | | |
Collapse
|
20
|
Zisman A, Pantuck AJ, Cohen JK, Belldegrun AS. Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology 2001; 58:988-93. [PMID: 11744474 DOI: 10.1016/s0090-4295(01)01422-4] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To describe a new surgical approach to third-generation cryoablation of the prostate and present our preliminary results. METHODS The technique is detailed and demonstrated in a Web-based video- clip tutorial. Ninety-two men underwent prostate cryoablation (71 primary ablations, 19 salvage procedures, and 2 repeated cryoablations), using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template. RESULTS No fistulous or major complications were observed. Eight patients (8.3%) had minor complications. In 36 patients, the follow-up period was long enough to permit nadir prostate-specific antigen (PSA) evaluation. In 31 (86%), the nadir PSA was 0.5 ng/mL or less. In 5 patients, the nadir PSA was greater than 0.5 ng/mL. The workup revealed systemic failure in 3 patients and inadequate eradication of the prostate gland in 2 patients. In 18 (86%) of 21 androgen-ablation-naive patients, the nadir PSA was 0.5 ng/mL or less. Nine (43%) had an undetectable nadir PSA and 3 had a nadir PSA of greater than 0.5 ng/mL. CONCLUSIONS A modified, less-invasive approach to cryoablation of the prostate is presented. The preliminary results do not show an increased rate of complications compared with other published series. The clinical outcome data are preliminary. Longer follow-up data are required to draw conclusions concerning efficacy.
Collapse
Affiliation(s)
- A Zisman
- Division of Urologic Oncology, Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
| | | | | | | |
Collapse
|
21
|
Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. J Urol 2001; 166:2242-6. [PMID: 11696744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
PURPOSE We studied the possible association of transrectal ultrasound guided prostate biopsy with voiding impairment. MATERIALS AND METHODS A total of 211 consecutive patients were prospectively enrolled. International Prostate Symptom Score (I-PSS), subjective voiding complaints and retention were recorded in 3 personal interviews before biopsy, and on postoperative days 7 and 30. RESULTS Of the 204 patients who voided via the urethra at biopsy 52 (25%) reported subjective voiding impairment on postoperative day 7, including 12% who defined difficult voiding as mild-1 to 2 points on a 0 to 5 scale, 8% as moderate-3/5 and 5% as severe-4 to 5/5. In 5 of the latter cases (2.5%) acute urinary retention necessitated urethral catheter insertion. Transition zone volume, which was 42 ml. or larger in all patients in urinary retention, was the only independent variable associated with patient report of subjective difficult voiding and acute urinary retention during week 1 after biopsy (p = 0.03). Baseline I-PSS greater than 20 points indicated a risk of an acute transient increase in I-PSS on postoperative day 7. CONCLUSIONS Transient voiding impairment may be precipitated by ultrasound guided prostate biopsy. To decrease this morbidity appropriate evaluation and possible treatment for bladder outlet obstruction are justified in patients with a larger transition zone and in those with preoperative baseline I-PSS greater than 20 points.
Collapse
Affiliation(s)
- A Zisman
- Department of Urology, Assaf-Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Zerifin, Israel
| | | | | | | | | | | |
Collapse
|
22
|
Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 2001; 24:459-71. [PMID: 11759069 DOI: 10.1097/00002371-200111000-00003] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The cytotoxic efficacy and kinetics involved in sensitization of Apo2L/TRAIL-resistant, androgen-independent prostate cancer cells to Apo2L/TRAIL or tumor necrosis factor-alpha or Fas ligand-mediated apoptosis were tested using subclinical concentrations of actinomycin D, paclitaxel, cisplatinum, gemcitabine, and radiation in CL-1, LNCaP, DU-145, and PC3 prostate cancer cell lines. CL-1 cells expressed all four Apo2L/TRAIL receptors and were resistant to Apo2L/TRAIL-mediated apoptosis (1-5,000 ng/mL) and to the sensitizers when given alone. Pretreatment with actinomycin D followed by Apo2L/TRAIL or tumor necrosis factor-alpha or anti-Fas CH-11 monoclonal antibody, but not in the reverse order, induced apoptosis in all cell lines. Synergistic sensitization in CL-1 cells was shown also with gemcitabine but not with cisplatinum, VP-16, paclitaxel, or radiation. Incubating the Apo2L/TRAIL-resistant CL-1, LNCaP, DU-145, and PC3 cell lines with 100 ng/mL actinomycin D for 4 hours followed by Apo2L/TRAIL for 24 hours resulted in 45.4 +/- 10.3%, 58.8 +/- 3.6%, 53.4 +/- 1.4%, and 84.2 +/- 8.4% apoptosis, respectively. Prolonging the sensitization time to 24 hours followed by 20 hours of incubation with Apo2L/TRAIL further enhanced the killing activity against CL-1 cells to 89 +/- 1% (delta = 60%, synergistic ratio = 3.1). This killing has a biphasic pattern that was contributed to by apoptosis (83%) and necrosis (17%) at 10 hours (peak) and 40% and 60%, respectively, at 20 hours. These results suggest that prostate cancer cells' resistance to Apo2L/TRAIL-mediated apoptosis can be reversed and synergy is achieved by sensitization of tumor cells with subclinical concentrations of actinomycin D or gemcitabine and may be useful clinically for the treatment of metastatic hormone- and drug-refractory prostate cancer.
Collapse
Affiliation(s)
- A Zisman
- Department of Urology, UCLA School of Medicine, University of California at Los-Angeles, 90095, USA
| | | | | | | | | |
Collapse
|
23
|
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-23. [PMID: 11586189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE Our understanding of the natural history of renal cell carcinoma, the role of nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are evolving and being integrated with advances in classification and staging. We reviewed the relevant literature to clarify these pertinent questions and provide a current review of the changes in the epidemiology, treatment and prognosis of patients with renal cell carcinoma. MATERIALS AND METHODS We comprehensively reviewed the peer reviewed literature on the current management of and results of treatment for renal cell carcinoma. RESULTS The incidence of and mortality from renal cell carcinoma have continuously increased during the last 50 years. Despite this increase in the number of new patients and consequently the number of deaths yearly the percent of those surviving for 5 years has notably improved. Factors related to improved survival include advances in renal imaging, earlier diagnosis, improved staging, better understanding of prognostic indicators, refinement in surgical technique and the introduction of immunotherapy approaches for advanced disease. CONCLUSIONS Currently patients with localized and metastatic renal cell carcinoma have had improvements in outlook and the therapeutic options available have expanded.
Collapse
Affiliation(s)
- A J Pantuck
- Department of Urology, University of California School of Medicine, Los Angeles, California, USA
| | | | | |
Collapse
|
24
|
Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 2001; 61:7925-33. [PMID: 11691814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Immunotherapy targeting for the induction of a T-cell-mediated antitumor response in patients with renal cell carcinoma (RCC) appears to hold significant promise. Here we describe a novel RCC vaccine strategy that allows for the concomitant delivery of dual immune activators: G250, a widely expressed RCC associated antigen; and granulocyte/macrophage-colony stimulating factor (GM-CSF), an immunomodulatory factor for antigen-presenting cells. The G250-GM-CSF fusion gene was constructed and expressed in Sf9 cells using a baculovirus expression vector system. The Mr 66,000 fusion protein (FP) was subsequently purified through a 6xHis-Ni2+-NTA affinity column and SP Sepharose/fast protein liquid chromatography. The purified FP retains GM-CSF bioactivity, which is comparable, on a molar basis, to that of recombinant GM-CSF when tested in a GM-CSF-dependent cell line. When combined with interleukin 4 (IL-4; 1000 units/ml), FP (0.34 microg/ml) induces differentiation of monocytes (CD14+) into dendritic cells (DCs) expressing surface markers characteristic for antigen-presenting cells. Up-regulation of mature DCs (CD83+CD19-; 17% versus 6%) with enhanced expression of HLA class I and class II antigens was detected in FP-cultured DCs as compared with DCs cultured with recombinant GM-CSF. Treatment of peripheral blood mononuclear cells (PBMCs) with FP alone (2.7 microg/10(7) cells) augments both T-cell helper 1 (Th1) and Th2 cytokine mRNA expression (IL-2, IL-4, GM-CSF, IFN-gamma, and tumor necrosis factor-alpha). Comparison of various immune manipulation strategies in parallel, bulk PBMCs treated with FP (0.34 microg/ml) plus IL-4 (1000 units/ml) for 1 week and restimulated weekly with FP plus IL-2 (20 IU/ml) induced maximal growth expansion of active T cells expressing the T-cell receptor and specific anti-RCC cytotoxicity, which could be blocked by the addition of anti-HLA class I, anti-CD3, or anti-CD8 antibodies. In one tested patient, an augmented cytotoxicity against lymph node-derived RCC target was determined as compared with that against primary tumor targets, which corresponded to an 8-fold higher G250 mRNA expression in lymph node tumor as compared with primary tumor. The replacement of FP with recombinant GM-CSF as an immunostimulant completely abrogated the selection of RCC-specific killer cells in peripheral blood mononuclear cell cultures. All FP-modulated peripheral blood mononuclear cell cultures with antitumor activity showed an up-regulated CD3+CD4+ cell population. These results suggest that GM-CSF-G250 FP is a potent immunostimulant with the capacity for activating immunomodulatory DCs and inducing a T-helper cell-supported, G250-targeted, and CD8+-mediated antitumor response. These findings may have important implications for the use of GM-CSF-G250 FP as a tumor vaccine for the treatment of patients with advanced kidney cancer.
Collapse
MESH Headings
- Animals
- Antigen Presentation/immunology
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Baculoviridae/genetics
- Cancer Vaccines/genetics
- Cancer Vaccines/immunology
- Carcinoma, Renal Cell/blood
- Carcinoma, Renal Cell/immunology
- Carcinoma, Renal Cell/therapy
- Cytokines/biosynthesis
- Cytokines/genetics
- Dendritic Cells/cytology
- Dendritic Cells/immunology
- Gene Expression Regulation, Neoplastic
- Granulocyte-Macrophage Colony-Stimulating Factor/genetics
- Granulocyte-Macrophage Colony-Stimulating Factor/immunology
- Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
- Humans
- Kidney Neoplasms/blood
- Kidney Neoplasms/immunology
- Kidney Neoplasms/therapy
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/metabolism
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Spodoptera/virology
- T-Lymphocytes, Cytotoxic/immunology
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- C L Tso
- Department of Urology, UCLA Kidney Cancer Program, University of California Los Angeles, Los Angeles, California 90095, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kleinmann J, Siegel Y, Cipele H, Goren E, Zisman A, Leibovici D, Lindner A. Factors affecting tube dwelling time after percutaneous nephrolithotomy. J Endourol 2001; 15:793-5. [PMID: 11724116 DOI: 10.1089/089277901753205762] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND AND PURPOSE Little is known about the impact of nephrostomy tubes on morbidity and quality of life. PATIENTS AND METHODS The tube dwelling time and the factors influencing it were determined in 165 patients undergoing percutaneous nephrolithotomy (PCNL). RESULTS The mean tube dwelling time was 21+/-30 days. The duration of tube drainage after PCNL was 13+/-17 days. Most of this time was preoperative when the tube was inserted for urgent reasons--obstruction or sepsis (31+/-33 days). On multivariate analysis, the number of secondary PCNLs and postoperative complications were the most significant factors affecting tube dwelling time. Age correlated with intubation time but did not reach statistical significance (P < 0.09). Neither the stone's side and type nor the patient's sex had a significant influence. CONCLUSIONS A significant factor affecting the duration of tube drainage is preoperative medical evaluation and patient preparation, and these steps should be completed expeditiously in order to minimize the time to PCNL. Completion of PCNL in one session should shorten the postoperative intubation time.
Collapse
Affiliation(s)
- J Kleinmann
- Urology Department, Assaf Harofeh Medical Center, Zerifin, Israel
| | | | | | | | | | | | | |
Collapse
|
26
|
Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001; 19:3792-3. [PMID: 11533107 DOI: 10.1200/jco.2001.19.17.3792] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Abstract
Conventional therapy for metastatic renal cell carcinoma is associated with a poor response rate and few patients are long-term survivors. The occurrence of spontaneous regression and the prolonged latency period between primary tumor removal and the appearance of metastases in some patients suggest the existence of important host immune responses to autologous tumor cells. With the advent of molecular gene transfer techniques and increased knowledge of the basic pathways of immune activation, the field of cancer immunotherapy has finally begun to develop novel and effective approaches for harnessing the immune system as a therapeutic agent. Current immunotherapy and gene therapy strategies, including methods of cytokine delivery and tumor-cell-based vaccines, are presented.
Collapse
Affiliation(s)
- A J Pantuck
- Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA.
| | | | | |
Collapse
|
28
|
Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001; 108:153-60. [PMID: 11435467 PMCID: PMC353719 DOI: 10.1172/jci10294] [Citation(s) in RCA: 148] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Using cre/loxP gene targeting, transgenic mice with muscle-specific inactivation of the GLUT4 gene (muscle GLUT4 KO) were generated and shown to develop a diabetes phenotype. To determine the mechanism, we examined insulin-stimulated glucose uptake and metabolism during hyperinsulinemic-euglycemic clamp in control and muscle GLUT4 KO mice before and after development of diabetes. Insulin-stimulated whole body glucose uptake was decreased by 55% in muscle GLUT4 KO mice, an effect that could be attributed to a 92% decrease in insulin-stimulated muscle glucose uptake. Surprisingly, insulin's ability to stimulate adipose tissue glucose uptake and suppress hepatic glucose production was significantly impaired in muscle GLUT4 KO mice. To address whether these latter changes were caused by glucose toxicity, we treated muscle GLUT4 KO mice with phloridzin to prevent hyperglycemia and found that insulin-stimulated whole body and skeletal muscle glucose uptake were decreased substantially, whereas insulin-stimulated glucose uptake in adipose tissue and suppression of hepatic glucose production were normal after phloridzin treatment. In conclusion, these findings demonstrate that a primary defect in muscle glucose transport can lead to secondary defects in insulin action in adipose tissue and liver due to glucose toxicity. These secondary defects contribute to insulin resistance and to the development of diabetes.
Collapse
Affiliation(s)
- J K Kim
- Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06536-8012, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 2001; 166:54-8. [PMID: 11435822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
PURPOSE We analyzed the effects of the change in TNM classification from the 1987 to the 1997 version and suggest a modified tumor size cutoff point between T stages 1 and 2 for renal cell carcinoma. MATERIALS AND METHODS We evaluated a database containing the records of 661 patients who underwent nephrectomy between 1989 and 1999. The effect of the change in TNM classification on the distribution of patients between stages, the rates of M+ and N+ disease, and the local and distant recurrence rates were outlined for 280 patients with T stages 1 and 2 disease. The Cox model was used to identify the optimal cutoff point between T1 and T2 disease, and the resulting effect of adopting this cutoff was outlined. RESULTS A total of 174 and 128 cases were down staged from 1987 version stage T2 to 1997 version stage T1 and from 1987 TNM stage II to 1997 TNM stage I, respectively. Survival was not significantly different in patients with 1997 TNM stages I and II disease due to a lack of survival difference during the first 2 years of followup. Stage shift also caused an increase in average tumor size, the proportion of patients with high grade cancer, and M+ and N+ disease at diagnosis in 1997 stages T1 and T2 as well as an increase in the proportion of 1997 stage T2N0M0 cases at diagnosis with systemic failure. Analysis of 11 potential cutoff points between 1 and 10 cm. revealed that 4.5 cm. was most predictive of patients survival (hazards ratio 4.99, p = 0.0001). Using this cutoff resulted in improved discriminatory power of the TNM classification and a moderating effect on the distribution of patients, average tumor size, high grade disease, M+ and N+ disease at diagnosis, and systemic failure between T(14.5) and T(24.5) compared with 1997 T1 and T2. CONCLUSIONS Our data imply that the current cutoff point of 7 cm. between stages T1 and T2 tumors is too high. Lowering the cutoff to 4.5 cm. resulted in better discriminatory power of the TNM classification in our dataset. This observation should be further validated by external data.
Collapse
Affiliation(s)
- A Zisman
- Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Leibovici D, Zisman A, Siegel YI, Lindner A. Cryosurgical ablation for prostate cancer: preliminary results of a new advanced technique. Isr Med Assoc J 2001; 3:484-7. [PMID: 11791412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
BACKGROUND Cryosurgery is a minimally invasive treatment option for prostate cancer. OBJECTIVES To report on the first series of cryosurgical ablation for prostate cancer performed in Israel. METHODS Cryosurgical ablation of the prostate was undertaken in 12 patients aged 53-72 diagnosed with adenocarcinoma of the prostate. The procedures were performed percutaneously and were monitored by real-time trans-rectal ultrasound. The CRYOHIT machine applying Argon gas was used with standard or ultra-thin cryoprobes. The average follow-up was 12.8 months postsurgery (range 1-24 months). RESULTS No rectal or urethral injuries occurred and all patients were discharged from hospital within 24-48 hours. The duration of suprapubic drainage was 14 days in 10 patients and prolonged in 2. Early complications included penoscrotal edema in four patients, perineal hematoma in three, hemorrhoids in two and epidydimitis in one. Long-term complications included extensive prostatic sloughing in one patient and a perineal fistula in another, both of whom required prolonged suprapubic drainage. Minimal stress incontinence was noted in two patients for the first 8 weeks after surgery. None of the patients has yet regained spontaneous potency. A prostate-specific antigen nadir of less than 0.5 ng/ml was achieved in eight patients and an undetectable PSA level below 0.1 ng/ml in five patients. CONCLUSION Cryoablation for prostate cancer is safe and feasible, and the preliminary results are encouraging. Further study is needed to elucidate the efficacy of the procedure.
Collapse
Affiliation(s)
- D Leibovici
- Department of Urology, Assaf Harofeh Medical Center, Zerifin, Israel
| | | | | | | |
Collapse
|
31
|
Abstract
The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.
Collapse
Affiliation(s)
- S J Freedland
- University of California, Los Angeles School of Medicine, Department of Urology, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA
| | | | | | | | | |
Collapse
|
32
|
Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12:883-92. [PMID: 11387054 DOI: 10.1089/104303401750195854] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Twenty-four patients with locally advanced prostate cancer (CaP) were enrolled in a phase I clinical trial using gene-based immunotherapy. A functional DNA-lipid complex encoding the interleukin 2 (IL-2) gene (Leuvectin; Vical, San Diego, CA) was administered intraprostatically into the hypoecogenic tumor lesion, using transrectal ultrasound guidance. Two groups of patients having locally advanced tumors were enrolled to receive a treatment regimen composed of two serial intraprostatic injections of the IL-2 gene agent administered 1 week apart. The first groups of patients included radical prostatectomy candidates who subsequently underwent surgery after the completion of the treatment regimen. The second group consisted of patients who had failed a prior therapy. Prostate specimens of the treated areas were attained after treatment and compared with the transrectal biopsies performed at baseline to assess for any responses. IL-2 gene therapy was well tolerated, with no grade 3 or 4 toxic reactions occurring. The most commonly reported symptoms were mild hematuria, transient rectal bleeding, and perineal discomfort that are likely attributable to the injection itself. During the entire course of treatment, there were no significant changes in American Urologic Association (AUA) symptom scores, in hematologic disturbances, electrolyte imbalances, or hepatic functions. Evidence of systemic immune activation was observed after IL-2 gene therapy, based on an increase in the intensity of T cell infiltration seen on immunohistochemical analysis of tissue samples from the injected tumor sites, and based on increased proliferation rates of peripheral blood lymphocytes that were cocultured with patient serum collected after treatment. Furthermore, transient decreases in serum prostate-specific antigen (PSA) (responders) were seen in 16 of 24 patients (67%) on day 1. Fourteen of the patients persisted in this decrease to day 8 (58%). In eight patients the PSA level rose (nonresponders). More patients (9 to 10) in the group that failed prior therapy responded to the IL-2 gene injections (chi-square test, p = 0.04), and 6 of the 9 also had lower than baseline PSA levels at week 10 after treatment. To the best of our knowledge, this is the first clinical study of its kind aimed at exploring the role of IL-2-based gene therapy in CaP patients. This phase I trial demonstrated the safety of intraprostatic Leuvectin injection, with transient PSA-based responses seen after therapy.
Collapse
Affiliation(s)
- A Belldegrun
- Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Pantuck AJ, Zisman A, Belldegrun A. Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol 2001; 19:72-9. [PMID: 11354536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
Advances in our understanding of the pathogenesis, behavior, and importance of prognostic factors for renal cell carcinoma (RCC) have paved the way for increased sophistication in its classification and staging. In the past, lack of consistent classification and terminology for RCC histology and staging has complicated comparability of clinical studies looking at patient prognosis and response to treatment. In this review, the results of international consensus efforts to achieve uniform classification systems for RCC are outlined and some future directions are considered.
Collapse
Affiliation(s)
- A J Pantuck
- Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
| | | | | |
Collapse
|
34
|
Zisman A, Pantuck AJ, Belldegrun AS, Schulam PG. Laparoscopic radical nephrectomy. Semin Urol Oncol 2001; 19:114-22. [PMID: 11354531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
Most of the open renal procedures have been duplicated or approximated by laparoscopy. Past concerns about increased operative time, cost, resection completeness, and port site metastases are being overruled or put into perspective as experience with laparoscopic radical nephrectomy (LRN) is gained: necessary skills can be acquired, operative times are approaching those for open procedure, and a 14% difference in cost is counterbalanced by reduced postoperative expenditures. Moreover, LRN is acknowledged by its quality-of-life advantages-reduced morbidity and improved cosmetic outcome. Disease-free rate with LRN at last follow-up is 100% for TNM stage I and 89% +/- 6.6 for stage II (1997 classification). Complications are acceptable with an 8% to 35% incidence of minor complications and a 3% to 19% incidence of severe complications. Conversion to an open procedure occurs in 0% to 10% of cases. The procedure's limitations and the appropriate criteria for patient selection are evident. The learning process is believed to last for approximately 20 procedures and patient selection is based on both clinical criteria and one's insight on his location on the learning curve. Therefore, LRN is becoming the treatment of choice for most TNM stages I and II renal tumors. Moreover, recent data advocating pre-immunotherapy nephrectomy in metastatic patients may permit laparoscopic nephrectomy to further benefit selected metastatic patients by potentially shortening the time interval from nephrectomy to immunotherapy and improving immune responsiveness.
Collapse
Affiliation(s)
- A Zisman
- Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
| | | | | | | |
Collapse
|
35
|
Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 20:35-9. [PMID: 11250993 DOI: 10.1016/j.purol.2009.07.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Revised: 07/08/2009] [Accepted: 07/28/2009] [Indexed: 01/03/2023] Open
Abstract
PURPOSE To integrate stage, grade, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) into a clinically useful tool capable of stratifying the survival of renal cell carcinoma (RCC) patients. PATIENTS AND METHODS The medical records of 661 patients undergoing nephrectomy at University of California Los Angeles between 1989 and 1999 were evaluated. Median age was 61 years, male-to-female ratio was 2.2:1, and median follow-up was 37 months. Survival time was the primary end point assessed. Sixty-four possible combinations of stage, grade, and ECOG PS were analyzed and collapsed into distinct groups. The internal validity of the categorized was challenged by a univariate analysis and a multivariate analysis testing for the accountability of each UCLA Integrated Staging System (UISS) category against independent variables shown to have impact on survival. RESULTS Combining and stratifying 1997 tumor-node-metastasis stage, Fuhrman's grade and ECOG PS resulted in five survival stratification groups designated UISS, and numbered I to V. The projected 2- and 5-year survival for the UISS groups are as follows for the groups: I, 96% and 94%; II, 89% and 67%; III, 66% and 39%; IV, 42% and 23%; and V, 9% and 0%, respectively. UISS accounted for the significant variables in the variate analysis. CONCLUSION A novel system for staging and predicting survival for RCC integrating clinical variables is offered. UISS is simple to use and is superior to stage alone in differentiating patients' survival. Our data suggests that UISS is an important prognostic tool for counseling patients with various stages of kidney cancer. Further prospective large-scale validation with external data is awaited.
Collapse
Affiliation(s)
- A Zisman
- Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Pantuck AJ, Zisman A, Henderson D, Wilson D, Schreiber A, Belldegrun A. New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. Urology 2001; 57:95-9. [PMID: 11295604 DOI: 10.1016/s0090-4295(00)00950-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
For at least 100 years, immunologists have proposed activating the immune system to specifically target and eradicate autologous tumor cells. The idea that tumor cells can be recognized as foreign to the host's immune system is an essential concept of tumor immunology that was first postulated by Paul Ehrlich at the turn of the century. Anecdotal reports of spontaneous tumor regression have been presumed to be immunologically mediated. With the advent of molecular gene transfer techniques and increased knowledge of the regulation of the immune response, effective methods for harnessing the immune system as a therapeutic agent are finally being realized. Current results of clinical immune/gene therapy protocols will be reviewed with consideration towards the concept of cancer prevention.
Collapse
Affiliation(s)
- A J Pantuck
- UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738 , USA
| | | | | | | | | | | |
Collapse
|
37
|
Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649-57. [PMID: 11250993 DOI: 10.1200/jco.2001.19.6.1649] [Citation(s) in RCA: 524] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To integrate stage, grade, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) into a clinically useful tool capable of stratifying the survival of renal cell carcinoma (RCC) patients. PATIENTS AND METHODS The medical records of 661 patients undergoing nephrectomy at University of California Los Angeles between 1989 and 1999 were evaluated. Median age was 61 years, male-to-female ratio was 2.2:1, and median follow-up was 37 months. Survival time was the primary end point assessed. Sixty-four possible combinations of stage, grade, and ECOG PS were analyzed and collapsed into distinct groups. The internal validity of the categorized was challenged by a univariate analysis and a multivariate analysis testing for the accountability of each UCLA Integrated Staging System (UISS) category against independent variables shown to have impact on survival. RESULTS Combining and stratifying 1997 tumor-node-metastasis stage, Fuhrman's grade and ECOG PS resulted in five survival stratification groups designated UISS, and numbered I to V. The projected 2- and 5-year survival for the UISS groups are as follows for the groups: I, 96% and 94%; II, 89% and 67%; III, 66% and 39%; IV, 42% and 23%; and V, 9% and 0%, respectively. UISS accounted for the significant variables in the variate analysis. CONCLUSION A novel system for staging and predicting survival for RCC integrating clinical variables is offered. UISS is simple to use and is superior to stage alone in differentiating patients' survival. Our data suggests that UISS is an important prognostic tool for counseling patients with various stages of kidney cancer. Further prospective large-scale validation with external data is awaited.
Collapse
Affiliation(s)
- A Zisman
- Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Leibovici C, Zisman A, Kleinman J, Lindner A. [Cryosurgery in prostate cancer]. Harefuah 2001; 140:148-52. [PMID: 11242922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
39
|
Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol 2001; 165:445-54. [PMID: 11176394 DOI: 10.1097/00005392-200102000-00023] [Citation(s) in RCA: 145] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE We prospectively studied the impact of transrectal ultrasound guided prostate biopsy on patient well-being. MATERIALS AND METHODS We enrolled 211 consecutive men who underwent a total of 218 biopsy events in a questionnaire based survey focusing on pain, anxiety and erectile dysfunction risk factors. Surveys were administered before, and immediately, 1 week and 1 month after biopsy. Quantitative information on the intensity of symptoms and signs was obtained using a uniform grading system. RESULTS Intraoperative pain considered severe in 20% of the biopsy events was associated with pain in the first 24 hours postoperatively, leading to analgesic use in 10%. Inflammatory infiltrate in the biopsy core and younger patient age correlated with persistent pain on days 2 and 7 after biopsy, respectively. Preoperative anxiety was reported in 64% of biopsy events and predictive of intraoperative pain. Anxiety peaked before result disclosure. Erectile dysfunction attributed to anxiety in anticipation of biopsy was reported in 7% of cases. At days 7 and 30, 15% of previously potent patients reported erectile dysfunction. CONCLUSIONS The impact of prostate biopsy on patient well-being begins while waiting for the scheduled procedure. Shortening the anticipation period before results are disclosed and administering pre-biopsy anxiety decreasing measures may benefit patients. Analgesic therapy is recommended in younger patients, those reporting moderate to severe intraoperative pain and those with known prostatic inflammatory infiltrate. The risk of acute erectile dysfunction should be discussed cautiously with patients who are potent before biopsy.
Collapse
Affiliation(s)
- A Zisman
- Department of Urology, Assaf-Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Zerifin, Israel
| | | | | | | | | |
Collapse
|
40
|
Abstract
The incidence of renal cell carcinoma (RCC) is rising steadily, but the ability to cure patients with metastatic RCC unfortunately remains limited. Emerging interest in gene therapy performance and safety is expressed by patients, medical institutes, and other agencies. It has become evident that better understanding of the genetic impairments and immune pathophysiology in RCC is essential for future improvement in patient care. Clinical trials now underway that are focusing on genetic and immune impairments will hopefully lead to future breakthroughs in RCC therapy. This paper reviews available gene therapies and other related therapeutic approaches for RCC and lists some of the current clinical trials focused on molecular-based therapies.
Collapse
Affiliation(s)
- A Zisman
- University of California, School of Medicine, Department of Urology, Los Angeles 90095-1738, USA
| | | | | |
Collapse
|
41
|
Freedland SJ, Chao D, Pantuck AJ, Zisman A, Belldegrun AS. Rethinking staging and treatment for renal cell cancer. Rev Urol 2001; 3:162-3. [PMID: 16985713 PMCID: PMC1476054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
|
42
|
Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Rev Urol 2001; 3:99-101. [PMID: 16985697 PMCID: PMC1476044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
|
43
|
Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 2001; 3:85-93. [PMID: 16985695 PMCID: PMC1476038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
The search continues for better tumor markers to improve the rate of detection of transitional cell carcinoma (TCC) more quickly in larger populations and to predict the possibility of disease recurrence. Among several new tests currently being screened, telomerase and hyaluronic acid/hyaluronidase (HA/HAase) have shown sensitivity and specificity equal to or better than cytology, and other promising tumor markers are being investigated. Although no marker has yet replaced the need to perform cystoscopy and cytology, the new tests can minimize the cost and difficulty of screening and long-term surveillance of patients who have or are at risk for bladder cancer.
Collapse
|
44
|
Freedland SJ, Chao D, Pantuck AJ, Zisman A, Belldegrun AS. Determining the optimal treatment for advanced bladder cancer. Rev Urol 2001; 3:159-62. [PMID: 16985712 PMCID: PMC1476051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
|
45
|
Freedland SJ, Bui MH, Chao D, Pantuck AJ, Zisman A, Belldegrun AS. Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Rev Urol 2001; 3:210-2. [PMID: 16985721 PMCID: PMC1476060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
|
46
|
Abstract
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar nonketotic syndrome (HHNS) are life-threatening acute metabolic complications of diabetes mellitus. Although there are some important differences, the pathophysiology, the presenting clinical challenge, and the treatment of these metabolic derangements are similar. Each of these complications can be seen in type 1 or type 2 diabetes, although DKA is usually seen in patients with type 1 diabetes and HHNS in patients with type 2 disease. The clinical management of these syndromes involves careful evaluation and correction of the metabolic and volume status of the patient, identification and treatment of precipitating and comorbid conditions, a smooth transition to a long-term treatment regimen, and a plan to prevent recurrence.
Collapse
Affiliation(s)
- M F Delaney
- Endocrinology-Hypertension Division, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | | | | |
Collapse
|
47
|
Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. Predicting CAP in patients with intermediate PSA using modified PSA indices. Can J Urol 2000; 7:1144-8. [PMID: 11151095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
OBJECTIVES To test a new PSA index: peripheral zone fraction PSA (PSA-PZ) and evaluate its' predictive value in patients with intermediate PSA. METHODS Fifty seven of 273 patients with serum PSA 4-10 ng/ml had CAP (21%). Total prostate volume and transition zone volume were calculated. Different cut-off points were used to calculate specificity, sensitivity, efficacy, positive and negative predictive values for PSA, PSAD, PSA-TZ and PSA-PZ (PSA-PZ= serum PSA((Total gland volume-TZ volume)/(Total gland volume)) RESULTS The distribution of PSA-PZ is presented. PSA-PZ is shown to be effective in DRE negative patients with serum PSA 4-10 ng/ml. For patients with PSA-PZ (1.5 ng/ml the biopsy may be spared with no cancer being missed. CONCLUSIONS The mathematical formula for PSA-PZ is straightforward and easy to use. Its application is convenient in the clinical setting. We suggest the use of PSA-PZ mainly in DRE negative patients having large glands and serum PSA between 4-10.
Collapse
Affiliation(s)
- A Zisman
- Urology Department, Assaf-Harofeh Medical Centre, Zerifin, Israel
| | | | | | | | | |
Collapse
|
48
|
Mauvais-Jarvis F, Virkamaki A, Michael MD, Winnay JN, Zisman A, Kulkarni RN, Kahn CR. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes 2000; 49:2126-34. [PMID: 11118016 DOI: 10.2337/diabetes.49.12.2126] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Type 2 diabetes is a polygenic disease characterized by defects in both insulin secretion and insulin action. We have previously reported that isolated insulin resistance in muscle by a tissue-specific insulin receptor knockout (MIRKO mouse) is not sufficient to alter glucose homeostasis, whereas beta-cell-specific insulin receptor knockout (betaIRKO) mice manifest severe progressive glucose intolerance due to loss of glucose-stimulated acute-phase insulin release. To explore the interaction between insulin resistance in muscle and altered insulin secretion, we created a double tissue-specific insulin receptor knockout in these tissues. Surprisingly, betaIRKO-MIRKO mice show an improvement rather than a deterioration of glucose tolerance when compared to betaIRKO mice. This is due to improved glucose-stimulated acute insulin release and redistribution of substrates with increased glucose uptake in adipose tissue and liver in vivo, without a significant decrease in muscle glucose uptake. Thus, insulin resistance in muscle leads to improved glucose-stimulated first-phase insulin secretion from beta-cells and shunting of substrates to nonmuscle tissues, collectively leading to improved glucose tolerance. These data suggest that muscle, either via changes in substrate availability or by acting as an endocrine tissue, communicates with and regulates insulin sensitivity in other tissues.
Collapse
Affiliation(s)
- F Mauvais-Jarvis
- Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Leibovici D, Zisman A, Chen-Levyi Z, Cypele H, Siegel YI, Faitelovich S, Lindner A. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000; 164:1546-9. [PMID: 11025701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
PURPOSE We determined whether intravesical bacillus Calmette-Guerin (BCG) instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS We treated 36 consecutive patients with bladder cancer with a 6-week course of BCG, followed by cystoscopy at 6 weeks. Blood samples for PSA determination were obtained before each BCG instillation and at cystoscopy with each patient also serving as a control. PSA elevation was defined as 2-fold the baseline level in at least 2 specimens and any PSA level greater than 4 ng./ml. was considered clinically significant. Digital rectal examination was done to identify firm nodules and prostate size. The prostate was examined histologically by transrectal ultrasound guided biopsy or after radical cystectomy. RESULTS We observed elevated PSA in 27 men (75%) during BCG treatment, of whom 15 (41.6%) had a clinically significant elevation. Overall average PSA increased from 1.3 ng./ml. before BCG instillation to 3.8 during treatment (range 0.1 to 21.5, p <0.0001). In those with a clinically significant elevation average PSA increased from 2.31 ng./ml. at baseline to 6.97 during treatment (p <0.0001) and returned to 3.86 ng./ml. 3 months after treatment. Palpation demonstrated prostatic findings in 10 patients, including firm nodules in 7, while there was significantly elevated PSA in 5 with firm nodules and 2 with diffuse prostatic enlargement. Histological examination of the prostate in 10 patients was diagnostic for granulomatous prostatitis, nonspecific inflammation and benign prostatic hyperplasia in 3, 3 and 4, respectively, of whom none had prostate cancer. CONCLUSIONS Intravesical BCG therapy is associated with significantly elevated PSA in up to 40% of cases. This effect is self-limited and PSA reverts to normal in 3 months. Therefore, we suggest that prostate biopsy be withheld in such patients and PSA monitored.
Collapse
Affiliation(s)
- D Leibovici
- Department of Urology and Laboratory of Biochemistry, Assaf-Harofe Medical Center, Zerifin and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | | | | | | | | | | | | |
Collapse
|
50
|
Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol 2000; 164:1420-5. [PMID: 10992426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
PURPOSE The mechanisms responsible for tumor progression to androgen independence in prostate cancer (CaP) remain unknown. To characterize these changes and provide a basis for rational therapeutic strategies for advanced CaP, an in vivo model from a highly aggressive androgen independent CaP cell line with distinct cellular and molecular properties was developed. MATERIALS AND METHODS An aggressive androgen-independent cell line designated CL1 was derived from a slow-growing, and androgen-dependent, parental LNCaP cell line through in-vitro androgen-deprivation and selection. CL1 was stably transfected with a green fluorescence protein gene (CL1-GFP) and orthotopically injected into SCID mice. The pathologic behavior, histology, and molecular determinants of CL1 tumor and metastases were determined and characterized by standard light and fluorescent microscopy, and quantitative RT-PCR analysis. RESULTS CL1 is an anaplastic prostate cancer cell line which demonstrates extensive local invasion and metastases to various organs that can be visualized via GFP expression. When compared with parental LNCaP cells, RT-PCR analysis of the tumor revealed an over-expression of EGFR, b-FGF, VEGF, TGF-beta, IL-8, IL-6, and bcl-2 and a down regulated expression of the p53, E-cadherin and PTEN. In contrast to LNCaP cells, CL1 tumors express lower levels of androgen receptor and barely detectable PSA mRNA. CONCLUSIONS CL1-GFP represents an aggressive androgen-independent CaP tumor model derived through androgen deprivation whose pathologic development and molecular properties in animals resembles the clinical characteristics of hormone refractory prostate cancer (HRPC). Metastatic sites of CL1-GFP can be visualized with fluorescence microscopy offering a unique therapeutic model for the evaluation of drug sensitivity and other therapeutic modalities.
Collapse
Affiliation(s)
- B J Patel
- Department of Urology, University of California at Los Angeles, Los Angeles, California 90095-1738, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|